Shanghai Cancer Institute
Impact in
- Cancer Research top 2%
- MicroRNA in disease regulation
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Oncology top 5%
Papers in
- Cancer Research 676
- Cancer-related molecular mechanisms research 164
- Cancer, Hypoxia, and Metabolism 161
- MicroRNA in disease regulation 155
- Oncology 936
- Pancreatic and Hepatic Oncology Research 234
- Cancer Immunotherapy and Biomarkers 129
Shanghai Cancer Institute
3.4k papers receiving 144.7k citations
Peers
Comparison fields: 5 of 228
- Cancer Research 35.4k
- Oncology 32.3k
- Molecular Biology 72.4k
- Hepatology 7.1k
- Immunology 14.9k
Countries citing scholars working at Shanghai Cancer Institute
This map shows the geographic impact of research produced by authors working at Shanghai Cancer Institute. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by papers produced at Shanghai Cancer Institute with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shanghai Cancer Institute more than expected).
Fields of papers published by authors at Shanghai Cancer Institute
This network shows the impact of papers affiliated with Shanghai Cancer Institute at the time of their publication. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers affiliated with Shanghai Cancer Institute at the time of their publication.
About Shanghai Cancer Institute
In recent decades, authors affiliated with Shanghai Cancer Institute have published 4.1k papers, which have received a total of 175.5k indexed citations . Scholars at this organization have produced 676 papers in Cancer Research, 936 papers in Oncology, 167 papers in Hepatology, 1.5k papers in Molecular Biology and 398 papers in Immunology on the topics of RNA modifications and cancer (245 papers), Pancreatic and Hepatic Oncology Research (234 papers), Epigenetics and DNA Methylation (174 papers), Cancer-related molecular mechanisms research (164 papers), Cancer, Hypoxia, and Metabolism (161 papers), MicroRNA in disease regulation (155 papers), Nanoplatforms for cancer theranostics (131 papers) and Cancer Immunotherapy and Biomarkers (129 papers). Their work is cited by papers focused on Cancer Research (35.4k citations), Oncology (32.3k citations), Molecular Biology (72.4k citations), Hepatology (7.1k citations) and Immunology (14.9k citations). Authors at Shanghai Cancer Institute collaborate with scholars in China, United States and United Kingdom and have published in prestigious journals including International Journal of Cancer, Cancer Letters, Cancer Epidemiology Biomarkers & Prevention, PLoS ONE and Advanced Science. Some of Shanghai Cancer Institute's most productive authors include Yu‐Tang Gao, Wei Zheng, Xiao‐Ou Shu, Xianjun Yu, Hongyang Wang, Gong Yang, Jianren Gu, Xianghuo He, Yong-Bing Xiang and Honglan Li.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.